Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageGlaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q2 2026 · $146.7MThe company’s own SEC segment disclosure.
- Glaucoma$118.5M81%
- Corneal Health$28.2M19%
Glaukos Corporation (GKOS) reported revenue of $186M in Q2 2026 (quarter ended Jun 30, 2026), up 50% from the same quarter a year earlier. That came with a gross margin of 82% and net loss of $18M. For the full year FY2025, revenue was $507M (+32% year on year) and net income −$188M. Its largest product in Q2 2026 was Glaucoma at $119M, 81% of the disclosed total, well ahead of Corneal Health at 19%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Medical Devices
Ranks #15 of 29 by Smart Score